Vulvovaginal Candidiasis – Pipeline Review, H2 2015

“Vulvovaginal Candidiasis – Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Vulvovaginal Candidiasis – Pipeline Review, H2 2015’, provides an overview of the Vulvovaginal Candidiasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Vulvovaginal Candidiasis and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Vulvovaginal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products

Reasons to buy

– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”

“Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vulvovaginal Candidiasis Overview 6
Therapeutics Development 7
Pipeline Products for Vulvovaginal Candidiasis – Overview 7
Pipeline Products for Vulvovaginal Candidiasis – Comparative Analysis 8
Vulvovaginal Candidiasis – Therapeutics under Development by Companies 9
Vulvovaginal Candidiasis – Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Vulvovaginal Candidiasis – Products under Development by Companies 13
Vulvovaginal Candidiasis – Companies Involved in Therapeutics Development 14
Grupo Ferrer Internacional, S.A. 14
NovaDigm Therapeutics, Inc. 15
Viamet Pharmaceuticals, Inc. 16
Vulvovaginal Candidiasis – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
arasertaconazole – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CD-101 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Myc-102 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NDV-3 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NDV-3A – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VT-1161 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Vulvovaginal Candidiasis – Recent Pipeline Updates 35
Vulvovaginal Candidiasis – Dormant Projects 39
Vulvovaginal Candidiasis – Discontinued Products 40
Vulvovaginal Candidiasis – Product Development Milestones 41
Featured News & Press Releases 41
Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015 41
Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis 41
Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014 42
Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 42
Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 43
Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 44
Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 44
Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48″
“List of Tables
Number of Products under Development for Vulvovaginal Candidiasis, H2 2015 7
Number of Products under Development for Vulvovaginal Candidiasis – Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Comparative Analysis by Unknown Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Vulvovaginal Candidiasis – Pipeline by Grupo Ferrer Internacional, S.A., H2 2015 14
Vulvovaginal Candidiasis – Pipeline by NovaDigm Therapeutics, Inc., H2 2015 15
Vulvovaginal Candidiasis – Pipeline by Viamet Pharmaceuticals, Inc., H2 2015 16
Assessment by Monotherapy Products, H2 2015 17
Number of Products by Stage and Target, H2 2015 19
Number of Products by Stage and Mechanism of Action, H2 2015 21
Number of Products by Stage and Route of Administration, H2 2015 23
Number of Products by Stage and Molecule Type, H2 2015 25
Vulvovaginal Candidiasis Therapeutics – Recent Pipeline Updates, H2 2015 35
Vulvovaginal Candidiasis – Dormant Projects, H2 2015 39
Vulvovaginal Candidiasis – Discontinued Products, H2 2015 40″
“List of Figures
Number of Products under Development for Vulvovaginal Candidiasis, H2 2015 7
Number of Products under Development for Vulvovaginal Candidiasis – Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Assessment by Monotherapy Products, H2 2015 17
Number of Products by Top 10 Targets, H2 2015 18
Number of Products by Stage and Top 10 Targets, H2 2015 18
Number of Products by Top 10 Mechanism of Actions, H2 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 20
Number of Products by Top 10 Routes of Administration, H2 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 22
Number of Products by Top 10 Molecule Types, H2 2015 24
Number of Products by Stage and Top 10 Molecule Types, H2 2015 24″